Sanyou Bio Leads The Future Of Biotech With AI-Powered Antibody Platform

Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. has launched the "Sanyou Innovative Intelligent Antibody Design oneClick+ Platform," a cutting-edge tool powered by artificial intelligence, aimed at revolutionizing the antibody development process. This platform is designed to significantly speed up the research and creation of antibody-based therapeutics.

Central to the oneClick+ platform is its extensive database of antibody structures, which allows researchers to swiftly design and evaluate potential candidates. The platform supports the creation of various antibody formats, including IgG-like antibodies, nanobodies, and single-chain variable fragments. Users can input full or partial antibody sequences and utilize the platform’s advanced features to obtain detailed analyses, including physicochemical properties, possible mutations, and structural visualizations.

Sanyou Biopharmaceuticals highlights the platform's ability to automate many traditionally labor-intensive tasks in antibody design, aiming to streamline drug development for researchers. The company is confident that oneClick+ will become an essential tool for accelerating the discovery and development of innovative therapeutics

Dr. Guojun Lang, CEO of Sanyou Bio said, "The launch of the 'oneClick+' platform marks a significant step forward for Sanyou Bio in the field of intelligent antibody design. The convenience it offers will completely revolutionize the way users approach antibody design. We believe that the launch of the 'oneClick+' platform will provide our customers with an unprecedented experience and contribute to the intelligent development of the biopharmaceutical industry.”